Rybrevant (amivantamab-vmjw) vs Exkivity (mobocertinib)
Rybrevant (amivantamab-vmjw) vs Exkivity (mobocertinib)
Rybrevant (amivantamab-vmjw) and Exkivity (mobocertinib) are both targeted therapies for non-small cell lung cancer (NSCLC) but are used in different genetic contexts. Rybrevant is a bispecific antibody designed to target EGFR and MET receptor pathways and is approved for patients with NSCLC with EGFR exon 20 insertion mutations. In contrast, Exkivity is a tyrosine kinase inhibitor (TKI) specifically approved for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. The choice between the two would depend on individual patient factors, including previous treatments, specific genetic mutations, and overall health, and should be made in consultation with an oncologist.
Difference between Rybrevant and Exkivity
| Metric | Rybrevant (amivantamab-vmjw) | Exkivity (mobocertinib) |
|---|---|---|
| Generic name | Amivantamab-vmjw | Mobocertinib |
| Indications | Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations | Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations |
| Mechanism of action | Bispecific antibody that targets EGFR and MET receptors | Tyrosine kinase inhibitor that targets EGFR exon 20 insertion mutations |
| Brand names | Rybrevant | Exkivity |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Rash, infusion-related reactions, paronychia, etc. | Diarrhea, rash, nausea, vomiting, etc. |
| Contraindications | None known | None known |
| Drug class | Bispecific antibody | Tyrosine kinase inhibitor |
| Manufacturer | Janssen Biotech, Inc. | Takeda Pharmaceutical Company Limited |
Efficacy
Efficacy of Rybrevant (amivantamab-vmjw) for Lung Cancer
Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets epidermal growth factor receptor (EGFR) and MET receptor pathways, which are often implicated in the pathogenesis of non-small cell lung cancer (NSCLC). The efficacy of Rybrevant for the treatment of NSCLC was evaluated in a multicenter, open-label, single-arm clinical trial. This trial specifically focused on patients with NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy. The results demonstrated a significant response rate, with a portion of patients achieving partial or complete tumor shrinkage. The duration of response varied among patients, with some experiencing sustained benefits.
It is important to note that the use of Rybrevant is associated with a specific biomarker, the EGFR exon 20 insertion mutation, which must be identified through an FDA-approved test. The presence of this mutation is a critical factor in determining the appropriateness of Rybrevant for a particular patient with NSCLC. The drug's efficacy is contingent upon the presence of this genetic alteration, and it is not indicated for use in the broader NSCLC patient population without this mutation.
Efficacy of Exkivity (mobocertinib) for Lung Cancer
Exkivity (mobocertinib) is an oral tyrosine kinase inhibitor designed to target EGFR exon 20 insertion mutations in NSCLC. The approval of Exkivity was based on the results of a multicenter, open-label, non-randomized, phase 1/2 trial that included patients with metastatic NSCLC harboring these specific mutations. The trial's findings indicated that Exkivity led to a meaningful response rate, with a significant number of patients experiencing tumor reduction. The duration of response, similar to Rybrevant, varied among patients, but some had prolonged periods of disease control.
As with Rybrevant, Exkivity's use is predicated on the identification of EGFR exon 20 insertion mutations through an FDA-approved diagnostic test. The targeted nature of Exkivity's mechanism of action underscores the importance of molecular testing in the management of NSCLC. It is tailored for a subset of patients with this particular genetic profile and is not intended for use in NSCLC patients without the EGFR exon 20 insertion mutations.
Regulatory Agency Approvals
Rybrevant
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Exkivity
-
Food and Drug Administration (FDA), USA
Access Rybrevant or Exkivity today
If Rybrevant or Exkivity are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us